Kornimate/medical-research-clean huggingface dataset:
clinical significance of assesment of serum mirna-30a in childhood nephrotic syndrome

Conditions: Nephrotic Syndrome Steroid-Resistant

Summary: childhood nephrotic syndrome is the most frequent glomerular disease that presents during childhood,primarily owing to a disturbed immune function.this disease is characterized by alterations in selectivity at the glomerular capillary wall that lead to an inability to restrict the urinary loss of protein.

childhood nephrotic syndrome is the most frequent glomerular disease that presents during childhood,primarily owing to a disturbed immune function.this disease is characterized by alterations in selectivity at the glomerular capillary wall that lead to an inability to restrict the urinary loss of protein.the syndrome is characterized by the tetrad of nephrotic range proteinuria (\>40 mg/m2/hour), hypoalbuminemia (\<2.5 g/dl), generalized edema, and hyperlipidemia. it can be congenital or acquired.currently,serum albumin, lipids, and proteinuria are the common diagnostic markers of childhood ns, but these markers may not accurately predict the outcome of individual patients because of the heterogeneity of the disease. renal biopsy is more precise for establishing prognosis of renal outcome, but it has potential complications. repeated monitoring is technically difficult, particularly for children. therefore, there is still an urgent need to identify new non invasive diagnostic and prognostic biomarkers and new therapeutic targets for this disease.mirna-30a expression in the serum of patients with nephrotic syndrome and analyzed the correlation between mirna with largest over expression level and clinical features compared with healthy subjects.mirna-30a expression level in drug resistant nephrotic syndrome patients was obviously higher than the drug sensitive patients and up-regulated most significantly in mesangial proliferative glomerulonephritis among different pathological types, while it decreased most obviously in glomerular lesions. mirna-30a could be treated as the molecular marker in predict drug resistance, pathological type of nephrotic syndrome and follow up of resistant cases.

Eligibility criteria:
inclusion criteria: -nephrotic children aged from 2 to 18 that admitted to pediatric hospital. exclusion criteria: * congenital or infantile nephrotic syndrome * other kidney diseases * abnormal kidney function test
tap block and subacute pain in inguinal herniography

Conditions: Postoperative Pain

Summary: inguinal hernia repair with mesh has a high incidence of postoperative chronic pain. transversus abdominis plane block is a current intervention to support postoperative analgesia, however it is recently in research area how to be applied in different surgical areas to be more effective than intravenous opioids. subcostal transversus abdominis plane block is not advised but has not been studied to be effective for postoperative analgesia in inguinal herniography patients. this study aims to research the effect of subcostal transversus abdominis plane block in subacute postoperative pain after inguinal hernia repair

patients were divided into two groups, one is control and the second is subcostal transversus abdominis plane block (stap) group. after standard general anesthesia application, control group ( group i) had 1 gram of paracetamol and 100 mg of contramal just after starting surgical closure. group ii (stap) had 1 gram of paracetamol and 100 mg of contramal, after surgical closure transversus abdominis plane block in subcostal area was applied to the patient.

Eligibility criteria:
inclusion criteria: * asa i-iii * who were to undergo elective unilateral inguinal herniography with "mesh" under general anesthesia. exclusion criteria: * patients who have allergy to local anesthetics

Keywords: tap block subacute pain inguinal herniography
the effectiveness and efficacy of the combination of the integrated psychological therapy and metacognitive training.

Conditions: Schizophrenia

Summary: the combination of the integrated psychological therapy and metacognitive training in individuals with schizophrenia and treatment resistant schizophrenia. is it effective and efficacious?

individuals with schizophrenia and treatment resistant schizophrenia will participate on a group cognitive behavioral therapy and rehabilitation, in which integrated psychological therapy and metacognitive training are going to be implemented. the therapy will last 60 biweekly sessions. this is a non randomized trial. speed of processing, working memory, verbal memory, visual memory, reasoning and problem solving, social cognition, symptoms, functional outcome and recovery will be evaluated before, after therapy and in a 6 months follow up. mccb, social perception scale, the greek test for verbal memory, panss, who das 2. 0 (greek), psyrat and the recovery assessment scale will be used ih this study.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia * no relapse and hospitalization * ambulant psychiatric treatment exclusion criteria: * other psychotic disorders * relapse and hospitalization * substance abuse

Keywords: schizophrenia, treatment resistant schizophrenia, recovery
comparing clinical outcome of 2 different total knee prostheses: nexgen lps-flex versus agc

Conditions: Osteoarthritis, Knee

Summary: a randomized blinded study is conducted comparing 2 different knee prostheses. range of motion (rom), pain, feel of prosthesis, satisfaction and ability to do daily activities are registered at intervals up to one year postop, where patients are informed on which prosthesis they received. we want to: * determine whether an increased rom is achieved with a high-flex knee compared to a standard knee * and if so, does it matter

100 patients operated on with unilateral tkr are included and randomized to either prostheses. patients operated on with bilateral simultaneous tkr receive one of each prostheses but are blinded to which prosthesis is on which side. they have gait analyses performed preop and at intervals up to one year.

Eligibility criteria:
inclusion criteria: * age below 75 years and active * preop rom at least 120 degress flexion * bmi below 30 * intact ligaments exclusion criteria: * below 18 years * unable to understand language or purpose

Keywords: osteoarthritis, knee total knee arthroplasty range of motion satisfaction
effectiveness of intraoperative exparel for postoperative pain control in total knee arthroplasty

Conditions: Osteoarthritis; Total Knee Arthroplasty; Pain Management

Summary: does the use of periarticular exparel in total knee arthroplasty prove to more effectively manage post operative pain control than another local analgesic, ropivacaine, when both are used as part of a multimodal pain management approach? the investigators hypothesize that exparel, a bupivacaine liposomal injectable suspension, will improve total knee arthroplasty postoperative pain with significant improvement of early function outcomes.

the investigators use a double blind, controlled, randomized study to examine the effectiveness of periarticular exparel in total knee arthroplasty postoperative pain control as well as effect on early mobilization and length of hospital stay when compared to another local analgesic (ropivacaine) when both are used as part of a multimodal pain management approach.

Eligibility criteria:
inclusion criteria: * patient undergoing total knee arthroplasty with dr. j.h. declaire * 18 years of age or older * primary diagnosis of osteoarthritis of the knee * opioid naïve patient (according to fda guidelines) exclusion criteria: * prior knee replacement * prior use of narcotics for chronic pain management * inflammatory arthritis (rheumatoid arthritis, lupus, etc.) * unicompartmental knee replacement * bilateral total knee arthroplasty * opioid tolerant as defined by the fda: patients who are taking, for one week or longer, at least: \> 60 mg oral morphine/day \> 25μg transdermal fentanyl/hour \> 30 mg oral oxycodone/day \> 8 mg oral hydromorphone/day \> 25 mg oral oxymorphone/day

Keywords: total knee arthroplasty total knee replacement exparel liposomal bupivacaine ropivacaine postoperative pain management
mayzent (siponimod) onboarding of secondary progressive multiple sclerosis (spms) patients with msgo

Conditions: Secondary Progressive Multiple Sclerosis

Summary: this study was a retrospective, non-interventional, longitudinal, descriptive study. this study did not have a key underlying hypothesis, rather it was designed to explore the onboarding and adherence of spms patients in australia to mayzent (siponimod) treatment. initiating siponimod involves pre-screen tests, including a cyp2c9 genotype test to determine siponimod maintenance dosing, and patients underwent a 6-day titration prior to maintenance. the msgo platform was developed to support onboarding. it is an integrated digital platform that functions as a patient support service.


Eligibility criteria:
inclusion criteria * adult patients with spms as per the treating physician's clinical assessment (therapeutic goods administration \[tga\]-approved indication of mayzent). * expanded disability status scale (edss) of 3.0 to 6.5 (inclusive). * patients accessing mayzent via the mayzent experience program (mep) must have met the mep criteria, and if available, the pharmaceutical benefits scheme (pbs) restrictions recommended by the pharmaceutical benefits advisory committee (pbac). * patients accessing mayzent via the pbs must have met the pbs restrictions. exclusion criteria * patients who were contraindicated for mayzent treatment according to the tga-approved product information. * patients diagnosed with clinically isolated syndrome or primary progressive multiple sclerosis (ms).
rheumatoid arthritis extension trial for subjects who have participated in other pf-05280586 trials (reflections b328-04)

Conditions: Rheumatoid Arthritis

Summary: this extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-pfizer, as well as the safety and immunogenicity after transitioning from rituximab-us or rituximab-eu to rituximab-pfizer. this study will provide continued treatment access to subjects with active rheumatoid arthritis who have participated for at least 16 weeks in other studies in the rituximab pfizer program.


Eligibility criteria:
inclusion criteria: * willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. * participated for a minimum of 16 weeks after the initiation of the last course of treatment in a previous rheumatoid arthritis study in the rituximab-pfizer program within the past 2 months. exclusion criteria: * investigational site staff members or relatives of those site staff members or subjects who are pfizer employees directly involved in the conduct of the study. * initiated treatment with investigational agents or other biologics (including rituxan and mabthera) since participating in a previous rheumatoid arthritis study in the rituximab-pfizer program.

Keywords: extension trial rheumatoid arthritis rituximab
effect of kinesio-taping technique on oral feeding in late preterm infants

Conditions: Swallow; Preterm Infant; Newborn; Kinesiotaping; Sucking

Summary: difficulty in feeding among late preterm infants is one of the most significant factors contributing to prolonged hospitalization and re-admissions. by providing support to the sucking and swallowing muscles early in their development, the maturation process can be expedited, allowing for the safe early discharge of preterm infants. this study aims to investigate the effects of the kinesio taping technique on feeding muscles and assess feeding and swallowing function in late preterm infants using acoustic analysis of swallowing sounds.

problems such as poor nutrition, weak sucking, lack of suck-swallow-respiration coordination, low weight gain are among the factors increasing the risk of morbidity in late preterm infants. early support of sucking and swallowing muscles for the development of suck-swallow coordination can shorten the maturation process and provide early discharge of late preterm infants. the aim of this study is to document kinesiotape technique to support sucking and swallowing muscles for treating nutritional problems and for reducing nutrition risks and accelerating maturation. according to power of analysis of this study, 74 infants planned to assign to kinesiotaping group or control group randomly. in kinesiotaping group, infants feeding performance will be evaluated by measuring the amount of milk invested, maximum heart rate, oxygen saturation, speed of milk intake and counting the number of swallow during feeding. kinesiotape will be applied to masseter and hyoid muscles 24 hours later after the birth of the infant. infants will be evaluated before kinesiotape application, 3 hour later and 24 hour later after the application.

Eligibility criteria:
inclusion criteria: * infants born in baskent university ankara hospital, * age between 34-36.6 weeks exclusion criteria: * infants with multiple kongenital anomaly, * hypoxic ischemic encephalopathy, * intraventricular and intracranial hemorrhage, * necrotizing enterocolitis, * tracheoesophageal fistula, * diaphragmatic hernia, * hydrocephalus, * respiratory distress.

Keywords: swallow preterm infant newborn kinesiotaping sucking
evaluation of long-term buprenorphine plasma exposure

Conditions: Opioid-use Disorder

Summary: the study objective is to characterise the long-term plasma exposure to buprenorphine after stopping sublocade treatment. there are no interventions planned. this multicentre investigation will enroll participants from study rb-us-13-0003 (nct02510014) or both studies rb-us-13-0003 and indv-6000-301 (nct02896296) and who received at least 2 subcutaneous (sc) injections of sublocade. there are two parts to the study: part a consists of a single visit during which urine samples are collected to measure free buprenorphine and free norbuprenorphine concentrations; qualitative urine drug samples (uds) for opioids, including buprenorphine; quantitative uds for buprenorphine, norbuprenorphine and naloxone; and determination of creatinine concentration. blood samples are collected for the determination of buprenorphine and norbuprenorphine plasma concentrations. results on the quantitative uds performed in part a determine enrollment in part b: participants who provide a quantifiable (i.e., positive) result for buprenorphine and/or norbuprenorphine and a non-quantifiable (i.e., negative) result for naloxone meet continuation criteria to move on to part b if part b is still open to enrolment. part b consists of two visits 30 days apart in which the same tests are run as were done in part a.

data indicate that after discontinuing sublocade patients may have detectable concentrations of buprenorphine in plasma and urine for 12 months or longer. previous phase ii/iii studies did not evaluate the pharmacokinetics (pk) of buprenorphine beyond 2 months after the last injection; this study will characterize the long-term plasma exposure starting at least 12 months after the last injection. the study will also assess relationships between plasma drug concentrations, free drug concentrations in urine and urine drug screen (uds) results in order to provide refined guidance to patients and physicians with respect to long-term exposure to buprenorphine after stopping sublocade treatment.

Eligibility criteria:
inclusion criteria: * participated in study rb-us-13-0003 or both studies rb-us-13-0003 and indv-6000-301 and received at least 2 subcutaneous (sc) injections of sublocade * within 12 to 36 months post his or her last sublocade injection at the time of the screening visit * female individuals of childbearing potential must agree to have a pregnancy test administered prior to enrollment and throughout the study. pregnancy does not prohibit participation * willing to adhere to study procedures and provide written informed consent prior to the start of any study procedures. exclusion criteria: * received sublocade or any other long-acting buprenorphine product at any time after ending their participation in study rb-us-13-0003 or study indv-6000-301 * taken any buprenorphine (prescribed or illicit) within 3 weeks prior to the screening visit (study part a, visit 1)
pre- and postoperative probiotics administration in patients undergoing sleeve gastrectomy

Conditions: Weight Loss

Summary: patients will be randomized into 2 groups: * g1: patients undergoing sleeve gastrectomy as bariatric procedure and receiving pre- and postoperative probiotics * g2: patients undergoing sleeve gastrectomy as bariatric procedure and not receiving pre- or postoperative probiotics weight loss will be assessed 1 year after surgery

patients will be randomized into 2 groups: * g1: patients undergoing sleeve gastrectomy as bariatric procedure and receiving pre- and postoperative probiotics * g2: patients undergoing sleeve gastrectomy as bariatric procedure and not receiving pre- or postoperative probiotics preoperative probiotics scheme include: * saccharomyces boulardii ntc 5375 + enterococcus faecium ubef-41 + lactobacillus acidophilus la 14 during 15 days (between 6th and 4th weeks before surgery) * bifidobacterium lactis bl 04 + bifidobacterium breve bb 03 + bifidobacterium bifidum bb 06 + bifidobacterium longum bl 05 during 15 days (between 4th and 2nd weeks before surgery) * lactobacillus rhamnosus lr 32 + lactobacillus rhamnosus hn001 + lactobacillus acidophillus la 14 during 15 days (between 2nd week and the day before surgery) postoperative probiotics scheme include: * saccharomyces boulardii ntc 5375 + enterococcus faecium ubef-41 + lactobacillus acidophilus la 14 during 15 days (between 1st and 3rd weeks after surgery) * lactobacillus rhamnosus lr 32 + bifidobacterium lactis bl 04 + bifidobacterium longum bl 05 + lactobacillus salivarius ls 33 + lactobacillus acidophilus la 14 + bifidobacterium bifidum bgn 4 during 4 months (between 4th and 20th weeks after surgery. both groups will receive the same nutritional recommendations. 1 year after surgery, weight los will be assessed as primary outcome. secondary outcomes will include daibetes mellitus remission and dyslipidemia remission. weight loss will be assessed 1 year after surgery

Eligibility criteria:
inclusion criteria: * bmi \>40 * bmi \>35 associated to diabetes mellitus, hypertension, dyslipidemia or sleep apnea/hypopnea síndrome * patients undergoing laparoscopic sleeve gastrectomy as primary bariatric procedure exclusion criteria: * revisional surgery * patients with gastroesophageal reflux disease * patients planned for a sleeve gastrectomy as first step of a second malabsorptive procedure * patients with immune deficiencies or with chronic intake of immune supressor drugs * patients refusing to participate in the study
allogeneic mesenchymal stem cell transplantation in tibial closed diaphyseal fractures

Conditions: Tibial Fracture

Summary: this study is a case-control prospective, clinal trial to assess the safety and efficacy of the allogeneic adipose derived mesenchymal stem cell transplantation on the healing of recent tibial fracture in 40 patients.

in this study all eligible patients divided in 2 group.20 patients received allogeneic adipose derived mesenchymal stem cell in the fractured site (case group) and other patients received the placebo in the fractured site (control group) . to assess the outcomes, we will evaluate the patients at 2, 6 weeks and 3, 6 months after transplantation by: x-ray, bmd , vas and biochemical analysis with laboratory tests.

Eligibility criteria:
inclusion criteria: * age 18 to 65 years * the presence of tibial fracture based on x ray * tibial fracture is limited to diaphysial exclusion criteria: * addiction * pregnancy * liver or kidney disease or uncontrolled diabetes or heart and lung disease * immune deficiency

Keywords: allogenic adipose derived mesenchymal stem cell tibial fracture
dna pax1 and jam3 methylation for cervical cancer screening

Conditions: Cervical Cancer; Cervical Intraepithelial Neoplasia; DNA Methylation; Cancer Screening; Detection Accuracy

Summary: based on the previous study of nct03961191 and nct03960879, we performed this trial to further confirm the accuracy of host dna pax1 and jam3 methylation for cervical cancer screening. this study would provide profound basis for the approval of assay kit of dna methylation in china for cervical screening. three hospitals, including peking union medical college hospital, would enroll eligible patients in this study. the cervical cytology of 3 ml will be collected for the detection of dna pax1 and jam3 methylation, and the results will compared with the cervical histological pathology, which is achieved after collection of cervical cytology, by surgeries including loop electrosurgical excision procedure, cervical conization, total hysterectomy and others. the methylation testing would be double-blinded in operators and analysts. the retrospective and prospective parts will enroll at least 120 patients and at least 339 patients, respectively.


Eligibility criteria:
inclusion criteria: * with uterine cervix intact * aged 18 years or older * with accessible histological results of cervix * signed an approved informed consents * with accessible cervical cytology before harvesting cervical histology exclusion criteria: * not meeting all of the inclusion criteria
efficacy of ocrelizumab in autoimmune encephalitis

Conditions: Autoimmune Encephalitis

Summary: this pilot study is a randomized, double-blind, placebo controlled study of the efficacy of ocrelizumab in autoimmune encephalitis. subjects with new diagnosis of autoimmune encephalitis will be invited to enroll in this study. subjects will be randomized to receive ocrelizumab (an anti-cd20 therapy) or matched placebo, and will undergo three infusions over a six month period. subjects will complete clinical visits over the study period, during which safety monitoring and neuropsychological assessments will be performed to assess for signs of clinical worsening from encephalitis. the primary outcome of this study is the proportion of patients who fail to complete the twelve month period without clinical worsening, as defined by the protocol. subjects who experience early clinical worsening during the study may be offered open-label treatment with ocrelizumab at the discretion of the investigators.


Eligibility criteria:
inclusion criteria: 1. age 18 or greater 2. able to obtain informed consent from patient or appropriate designee 3. possible autoimmune encephalitis as defined by table 1: 1. reasonable exclusion of alternative causes 2. subacute onset (\< 3 months) of memory deficits, altered consciousness, and/or psychiatric symptoms 3. one or more of the following: * csf (cerebrospinal fluid) pleocytosis (\>5 cells/µl corrected, if necessary, for traumatic lumbar puncture) * eeg (electroencephalogram) with epileptiform or focal slow wave abnormalities involving temporal lobes * brain abnormalities on t2/flair mri restricted to the mesial temporal (limbic) lobes * associated dyskinesias (faciobrachial dystonic movements or orofacial dyskinesias) 4. completed initial treatment with iv steroids (at least 3000mg solumedrol) and plasma exchange (at least 3 exchanges) within the past 8 weeks 5. presence of one (or more) of the following autoantibodies in serum or csf * nmda receptor * lgi1 * caspr2 * dppx exclusion criteria: 1. prior immunosuppression treatment in past year (other than steroids, intravenous immunoglobulin and plasma exchange) 2. active malignancy requiring chemotherapy 3. pregnancy 4. evidence of active hepatitis or tuberculosis infection 5. medical condition that (in investigators opinion) precludes the use of ocrelizumab